Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 4 | 2016 | 967 | 1.190 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2016 | 68 | 0.700 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2016 | 3 | 0.510 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2016 | 9 | 0.500 |
Why?
|
| AIDS Dementia Complex | 1 | 2016 | 11 | 0.500 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2016 | 9 | 0.500 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2016 | 28 | 0.500 |
Why?
|
| Neoplasms | 2 | 2016 | 1361 | 0.470 |
Why?
|
| Viral Load | 1 | 2016 | 231 | 0.470 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 96 | 0.460 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 105 | 0.460 |
Why?
|
| RNA, Viral | 1 | 2016 | 276 | 0.450 |
Why?
|
| Mass Screening | 2 | 2016 | 693 | 0.420 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 538 | 0.350 |
Why?
|
| Hypertension | 1 | 2016 | 585 | 0.340 |
Why?
|
| Primary Health Care | 1 | 2016 | 690 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 834 | 0.290 |
Why?
|
| Toxoplasmosis, Cerebral | 2 | 2016 | 6 | 0.220 |
Why?
|
| Amphotericin B | 1 | 2003 | 23 | 0.210 |
Why?
|
| Antifungal Agents | 1 | 2003 | 127 | 0.200 |
Why?
|
| Comorbidity | 2 | 2016 | 1122 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 734 | 0.130 |
Why?
|
| Lamivudine | 1 | 2016 | 7 | 0.130 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 8 | 0.130 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2016 | 3 | 0.130 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2016 | 6 | 0.130 |
Why?
|
| Emtricitabine | 1 | 2016 | 8 | 0.130 |
Why?
|
| HIV Core Protein p24 | 1 | 2016 | 17 | 0.130 |
Why?
|
| Tenofovir | 1 | 2016 | 9 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 11 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 25 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 2016 | 16 | 0.130 |
Why?
|
| HIV-2 | 1 | 2016 | 23 | 0.120 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 19 | 0.120 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 23 | 0.120 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 17 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 93 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 94 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
|
| Candidiasis | 1 | 2016 | 51 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 53 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2016 | 165 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 54 | 0.120 |
Why?
|
| Lymphoma | 1 | 2016 | 102 | 0.120 |
Why?
|
| Criminal Law | 1 | 2016 | 82 | 0.120 |
Why?
|
| HIV Antibodies | 1 | 2016 | 146 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 69 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 99 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 463 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 141 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 517 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 129 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2016 | 208 | 0.100 |
Why?
|
| United States | 2 | 2016 | 7826 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 753 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 319 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2016 | 410 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2016 | 295 | 0.100 |
Why?
|
| Male | 5 | 2016 | 29823 | 0.100 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 18 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 47 | 0.090 |
Why?
|
| Humans | 7 | 2016 | 63299 | 0.090 |
Why?
|
| Coinfection | 1 | 2011 | 58 | 0.090 |
Why?
|
| Adult | 4 | 2016 | 16788 | 0.090 |
Why?
|
| Algorithms | 1 | 2016 | 1000 | 0.090 |
Why?
|
| HIV-1 | 1 | 2016 | 721 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2016 | 2076 | 0.080 |
Why?
|
| Pregnancy | 1 | 2016 | 2333 | 0.070 |
Why?
|
| Young Adult | 1 | 2016 | 4686 | 0.060 |
Why?
|
| Risk Factors | 1 | 2016 | 5343 | 0.060 |
Why?
|
| Adolescent | 1 | 2016 | 6241 | 0.060 |
Why?
|
| Female | 2 | 2016 | 32793 | 0.050 |
Why?
|
| Splenic Diseases | 1 | 2003 | 15 | 0.050 |
Why?
|
| Splenectomy | 1 | 2003 | 42 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 52 | 0.050 |
Why?
|
| Liposomes | 1 | 2003 | 103 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2003 | 36 | 0.050 |
Why?
|
| Abscess | 1 | 2003 | 79 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 14396 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2003 | 172 | 0.040 |
Why?
|
| Hospitals | 1 | 2003 | 392 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1255 | 0.040 |
Why?
|
| Middle Aged | 1 | 2016 | 17556 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2003 | 491 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2011 | 8 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 124 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 76 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2003 | 6635 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 2164 | 0.010 |
Why?
|